These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25842959)

  • 1. [When will the new tuberculosis vaccine appear?].
    Koroliuk AM; Zazimko LA; Petrovskiĭ SV
    Zh Mikrobiol Epidemiol Immunobiol; 2015; (1):86-94. PubMed ID: 25842959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant live vaccine candidates against tuberculosis.
    Kaufmann SH; Gengenbacher M
    Curr Opin Biotechnol; 2012 Dec; 23(6):900-7. PubMed ID: 22483201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant BCG vaccine candidates.
    Hernàndez-Pando R; Castañòn M; Espitia C; Lopez-Vidal Y
    Curr Mol Med; 2007 Jun; 7(4):365-72. PubMed ID: 17584076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Strategies for the development of new tuberculosis vaccines].
    Fattorini L
    Minerva Med; 2007 Apr; 98(2):109-19. PubMed ID: 17519853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis.
    Liang J; Teng X; Yuan X; Zhang Y; Shi C; Yue T; Zhou L; Li J; Fan X
    Mol Immunol; 2015 Aug; 66(2):392-401. PubMed ID: 25974877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quest for a new vaccine against tuberculosis.
    Delogu G; Fadda G
    J Infect Dev Ctries; 2009 Feb; 3(1):5-15. PubMed ID: 19749443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis.
    Singh S; Saraav I; Sharma S
    Vaccine; 2014 Feb; 32(6):712-6. PubMed ID: 24300592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis.
    Triccas JA; Shklovskaya E; Spratt J; Ryan AA; Palendira U; Fazekas de St Groth B; Britton WJ
    Infect Immun; 2007 Nov; 75(11):5368-75. PubMed ID: 17724075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
    Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
    J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel recombinant BCG-expressing pro-apoptotic protein BAX enhances Th1 protective immune responses in mice.
    Li G; Liu G; Song N; Kong C; Huang Q; Su H; Bi A; Luo L; Zhu L; Xu Y; Wang H
    Mol Immunol; 2015 Aug; 66(2):346-56. PubMed ID: 25942359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis vaccines: Opportunities and challenges.
    Zhu B; Dockrell HM; Ottenhoff THM; Evans TG; Zhang Y
    Respirology; 2018 Apr; 23(4):359-368. PubMed ID: 29341430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine and skin testing properties of two avirulent Mycobacterium bovis mutants with and without an additional esat-6 mutation.
    Collins DM; Kawakami RP; Wards BJ; Campbell S; de Lisle GW
    Tuberculosis (Edinb); 2003; 83(6):361-6. PubMed ID: 14623166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
    Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
    Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy.
    Ru H; Liu X; Lin C; Yang J; Chen F; Sun R; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():239. PubMed ID: 28642843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.
    Grode L; Seiler P; Baumann S; Hess J; Brinkmann V; Nasser Eddine A; Mann P; Goosmann C; Bandermann S; Smith D; Bancroft GJ; Reyrat JM; van Soolingen D; Raupach B; Kaufmann SH
    J Clin Invest; 2005 Sep; 115(9):2472-9. PubMed ID: 16110326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberculosis vaccine types and timings.
    Orme IM
    Clin Vaccine Immunol; 2015 Mar; 22(3):249-57. PubMed ID: 25540272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.